Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.48 |
| ▸ | MMP9 | P14780 | 5/20 | 0.48 |
| ▸ | MMP13 | P45452 | 4/20 | 0.48 |
| ▸ | MMP3 | P08254 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376946 | 0.95 | RAB9A (0.50) | MMP2MMP9MMP13MMP3HPGD | |
| SCHEMBL1376755 | 0.95 | KMT2A (0.47) | MMP2MMP9MMP13MMP3HPGD | |
| SCHEMBL1380239 | 0.94 | MMP2 (0.45) | MMP2MMP9MMP13MMP3HPGD | |
| Hydroxyamine SCHEMBL7481959 | 0.92 | MMP2 (0.44) | MMP2MMP9MMP13MMP3HPGD | |
| SCHEMBL5036997 | 0.89 | MMP13 (0.44) | MMP2MMP9MMP13MMP3HPGD | |
| SCHEMBL1381142 | 0.89 | MMP2 (0.41) | MMP2MMP9MMP13MMP3HPGD | |
| Hydroxyamine SCHEMBL1380759 | 0.88 | MMP2 (0.40) | MMP2MMP9MMP13MMP3HPGD | |
| SCHEMBL1376858 | 0.86 | MMP2 (0.53) | MMP2MMP9MMP13MMP3CA9 | |
| SCHEMBL1378426 | 0.86 | MMP2 (0.50) | MMP2MMP9MMP13MMP3HDAC1 | |
| SCHEMBL5031626 | 0.85 | MMP2 (0.49) | MMP2MMP9MMP13MMP3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4750272-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | claimed |
| US-6277987-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS | NOVARTIS AG (CH) | 2001-08-21 | — | — | US | claimed |
| EP-1053226-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | Novartis AG (CH) | 2000-11-22 | — | — | EP | claimed |
| WO-1999042443-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | claimed |
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-6410580-B1 | ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-6277987-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS | NOVARTIS AG (CH) | 2001-08-21 | — | — | US | disclosed |
| EP-1053226-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | Novartis AG (CH) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999042443-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | disclosed |